Drugs profiles

Mepitiostane is a 17-beta etherified derivative of epitiostane. This ether is necessary to allow for the product to be taken orally. The idea behind this drug’s deliver system is the same as that of Anabolicum Vister, which is for it to be absorbed through the lymphatic system. This drug was first developed in the 1960s, during investigations into a series of A-ring modified androstane derivatives. The only modern pharmaceutical preparation of this drug on record is Thioderon, which is sold in Japan by the pharmaceutical company Shinogi. The drug is used in Japanese medicine as an anabolic agent, and is mainly given to patients for the treatment of breast carcinoma and anemia associated with renal failure. The drug was never widely used outside of Japan and new medications which are equally effective make it even less useful today. Still, the drug remains available for sale, just not widely found outside of Japan. It is supplied in the form of capsules which contain 5mg of the steroid.

Trenbolone acetate is an injectable anabolic/androgenic steroid which is derived from the the steroid nandrolone. It’s activity however is quite different to the point that direct comparisons between the two are difficult to make. Trenbolone acetate is a non estrogenic steroid and is considerably both more anabolic and androgenic than its parent nandrolone on a milligram for milligram basis. Trenbolone acetate was first extensively studied in 1967, described during a series of studies of experiments into synthetic steroids. Trenbolone acetate is a drug of veterinary medicine which is used almost exclusively to increase the rate of weight gain and improve feed efficiency of cattle shortly before slaughter. Meat products sold in many areas of the world will often contain small amounts of residual trenbolone metabolites as a result of this practice. Human users of finaplix often purchase kits which are readily available online in order to convert the implant pellets into an injectable oil solution.

Winstrol is a classic “cutting” steroid in that it produces clean, solid (though slow and slight) gains without water retention. This is due to its molecular structure it cannot covert to estrogen. In fact is actually has ANTI estrogen effects due to being derived from DHT, (Dihydrotestosterone) therefore it has the ability to block SHBG. (Sex Hormone Binding Globulin).

It also has an anti progestrogenic effect and for that reason Winstrol is advised to be used in conjunction with Deca Durabolin to counteract the progesterone it produces. (Though it isn’t completely clear how this occurs).

Exemestane is a steroidal suicide aromatase inhibitor. It isvery similar in structure and action to formestane, although it is significantly more potent in comparison. As a class of drugs, aromatase inhibitors offer an anti estrogenic effect by blocking the enzyme responsible for synthesizing estrogens. Exemestane is approved by the FDA for the treatment of breast cancer in women, specifically in post menopausal patients whose cancer has progressed following therapy with tamoxifen (nolvadex). Male bodybuilders and athletes often use the drug for non approved purposes, namely to counter the estrogenic side effects associated with the use of aromatizable anabolic/androgenic steroids. This may include gynecomastia, fat buildup, and water retention. Exemestane is one of the most potent aromatase inhibitors presently available. The most commonly cited date reports a lowering of estrogen around 85% on average in clinical studies with women. Exemestane was developed by Pharmacia & Upjohn, which gained FDA approval for sale of the drug in late 1999. They introduced it under the Aromasin brand name in early 2000. Although the drug proved to be effective in doses as low as 2.5mg per day in some patients, the company developed it in a standard and near universally effective dosage of 25mg per tablet. The company has since introduced the drug to many other nations under the same trade name of Aromasin.

Aminoglutethimide is mainly identified as an inhibitor of adrenocortical steroid synthesis. Its primary function is to block the conversion of cholesterol to pregnenolone, which is required for the biosynthesis of adrenal glucocorticoids, mineral corticoids, estrogens, and androgens. Aminoglutethimide is a nonspecific inhibitor, and also blocks several other steps in steroid synthesis including hydroxylation at C-11, C-18, and C-21, and the aromatization of androgen to estrogens, The drug may be used clinically to treat estrogen dependent breast cancer, and to treat Cushing’s syndrome, which is a condition where the body overproduces the hormone cortical. The effect that Aminoglutethimide can have on cortical and estrogen production is what makes this a drug of interest to athletes and bodybuilders. The drug also works by inhibiting cortical production. While cortical is an essential hormone for life, its  levels may also vary greatly within “normal” ranges depending on the individual, their training and dietary status. Aminoglutethimide was FDA approved as an anticonvulsant drug in 1960 under the main trade name of Cytadren. Side effects were common with treatment, however, including drowsiness, dizziness, and partial loss of motor control. In 1966 reports of adrenal insufficiency subsequent to Aminoglutethimide use were reported. The drug was withdrawn from the U.S market as an anticonvulsant that same year due to its recently understood effects on the adrenal gland. The drug is most commonly supplied in tablets of 250mg.